A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.
Ira GantzTaro OkamotoYuka ItoAsako SatoKotoba OkuyamaEdward A O'NeillSamuel S EngelEseng Lainull nullPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2017)
MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.